<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="58654">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01850134</url>
  </required_header>
  <id_info>
    <org_study_id>BL18</org_study_id>
    <nct_id>NCT01850134</nct_id>
  </id_info>
  <brief_title>Evaluation of a Nutritional Supplement for People With Type 2 Diabetes.</brief_title>
  <official_title>Evaluation of a Nutritional Supplement for People With Type 2 Diabetes (T2DM).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Nutrition</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Nutrition</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this trial is to evaluate a nutritional supplement for people with
      Diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">July 2013</completion_date>
  <primary_completion_date type="Anticipated">July 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Hunger</measure>
    <time_frame>Treatment Visit 1 and Treatment Visit 2</time_frame>
    <safety_issue>No</safety_issue>
    <description>An appetite questionnaire evaluating change from baseline during each study visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fullness</measure>
    <time_frame>Treatment Visit 1 and Treatment Visit 2</time_frame>
    <safety_issue>No</safety_issue>
    <description>An appetite questionnaire evaluating change from baseline during each study visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Desire to Eat</measure>
    <time_frame>Treatment Visit 1 and Treatment Visit 2</time_frame>
    <safety_issue>No</safety_issue>
    <description>An appetite questionnaire evaluating change from baseline during each study visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prospective Consumption</measure>
    <time_frame>Treatment Visit 1 and Treatment Visit 2</time_frame>
    <safety_issue>No</safety_issue>
    <description>An appetite questionnaire evaluating change from baseline during each study visit.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Control Study Product</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 serving of control beverage.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental Study Product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 serving of a nutritional supplement for people with diabetes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Experimental Study Product</intervention_name>
    <arm_group_label>Experimental Study Product</arm_group_label>
    <other_name>Oral nutritional supplement for people with Diabetes.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control Study Product</intervention_name>
    <arm_group_label>Control Study Product</arm_group_label>
    <other_name>Water beverage.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects will be eligible for the study if they meet all of the following inclusion
             criteria:

               1. Diagnosis of Type 2 Diabetes.

               2. Age between 18 and 75 years.

               3. HbA1c &gt; 6.0 but â‰¤ 8.5

               4. If female and of childbearing potential , subject is non-pregnant, non-
                  lactating, at least 6 weeks postpartum and agrees to practice birth control
                  throughout study duration.

               5. BMI &gt; 18.5 kg/m2 and &lt; 40.0 kg/m2.

               6. Chronic medication dosage must be stable for at least two months prior to
                  Screening Visit.

               7. Subject states that they are a habitual consumer of a morning meal.

        Exclusion Criteria:

          -  Subjects will be excluded from the study if they meet any of the following criteria:

               1. Use of exogenous insulin or GLP-1 agonists for glucose control.

               2. Diagnosis of Type 1 diabetes.

               3. History of diabetic ketoacidosis.

               4. Current infection (requiring medication or hospitalization), has received
                  corticosteroid treatment in the last 3 months, or has had surgery or received
                  antibiotics in the last 3 weeks.

               5. Active malignancy.

               6. Significant cardiovascular event &lt; 12 weeks prior to study entry.

               7. End stage organ failure or status post organ transplant.

               8. Active metabolic, hepatic, or gastrointestinal disease.

               9. Chronic, contagious, infectious disease.

              10. Currently taking herbals, dietary supplements, or medications (other than
                  antihyperglycemic medications) that could profoundly affect blood glucose.

              11. History of fainting or other adverse reactions in response to blood collection.

              12. Clotting or bleeding disorders.

              13. Allergy or intolerance to study product ingredient.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amy Devitt-Maicher, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Abbott Nutrition</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kristen DeLuca, MS, RD, LD</last_name>
    <phone>614-624-5455</phone>
    <email>kristen.deluca@abbott.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bobbie Swearengin, RN</last_name>
    <phone>614-624-7182</phone>
    <email>bobbie.swearengin@abbott.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Biofortis Clinical Research</name>
      <address>
        <city>Addison</city>
        <state>Illinois</state>
        <zip>60101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Andrea Lawless, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45249</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Michael Noss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 7, 2013</lastchanged_date>
  <firstreceived_date>May 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
